Many experts agree that 2021 is the year of the liquid biopsy. Since diagnostics are our first love, we agree. However, with multi-million dollar valuations in the US for a whole raft of emerging players, we’ve had to work hard to convince editors that there are equally valuable companies here in Europe. Hard but successfully as you can see persuading diagnostics guru Ashley Yeo of MedtechInsight to write this profile of Elypta who are developing the first metabolic biomarker-based assay.